These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1464472)

  • 1. Reconstruction of anti-leprosy drug depleted complement haemolytic activity by addition of zymosan-treated sera (a source of C142) and CratEDTA (a source of C3-C9).
    Kashyap A; Saha K; Sehgal VN
    Int J Immunopharmacol; 1992 Nov; 14(8):1409-14. PubMed ID: 1464472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of anti-leprosy drugs with the rat serum complement system.
    Sahu A; Saha K; Kashyap A; Chakrabarty AK
    Immunopharmacology; 1988; 15(3):143-50. PubMed ID: 3134310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes.
    Lint TF; Behrends CL; Baker PJ; Gewurz H
    J Immunol; 1976 Nov; 117(5 Pt 1):1440-6. PubMed ID: 1002985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemolysis of normal human erythrocytes by autologous serum complement.
    Kitamura H; Nagano A; Kitano E
    Int Arch Allergy Immunol; 1993; 100(3):209-14. PubMed ID: 8453307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-leprosy drugs inhibit the complement-mediated solubilization of pre-formed immune complexes in vitro.
    Kashyap A; Sehgal VN; Sahu A; Saha K
    Int J Immunopharmacol; 1992 Feb; 14(2):269-73. PubMed ID: 1624226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Action of chlorogenic acid on the complement system.
    Ejzemberg R; Da Silva MH; Pinto L; Mors WB
    An Acad Bras Cienc; 1999; 71(2):273-7. PubMed ID: 10412494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro inhibition of the activation of the human complement and coagulation systems by chloroquine.
    Ramanathan VD; Sengupta U
    Int J Immunopharmacol; 1985; 7(5):769-73. PubMed ID: 4044101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
    Kitamura H; Tsuboi M
    Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of murine complement by cobra venom factor in the presence of EDTA.
    Goldman JN; Bangalore S; Goldman MB
    J Immunol; 1979 Nov; 123(5):2421-7. PubMed ID: 114590
    [No Abstract]   [Full Text] [Related]  

  • 10. Sheep serum complement sensitisation of sheep erythrocyte-rabbit antibody complexes for haemolysis by guinea-pig complement plus EDTA or Mg2+-EGTA.
    Jonas W; Stankiewicz M
    Arch Immunol Ther Exp (Warsz); 1986; 34(4):451-60. PubMed ID: 3099725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement lysis of human erythrocytes. III. Differing effectiveness of human and guinea pig C9 on normal and paroxysmal nocturnal hemoglobinuria cells.
    Rosenfeld SI; Packman CH; Jenkins DE; Countryman JK; Leddy JP
    J Immunol; 1980 Nov; 125(5):2063-8. PubMed ID: 6776186
    [No Abstract]   [Full Text] [Related]  

  • 12. Soluble C5b-9 complex of guinea pig complement: demonstration of its heterogeneity and the mechanism of its C9 hemolytic activity as transfer of reversibly bound C9 molecules from the complex.
    Kinoshita T; Hong K; Inoue K
    Mol Immunol; 1981 May; 18(5):423-31. PubMed ID: 7311977
    [No Abstract]   [Full Text] [Related]  

  • 13. Ability to activate the alternative complement pathway acquired by human and guinea-pig erythrocytes after contact with influenza virus.
    Lambré C; Thibon M
    Ann Immunol (Paris); 1980; 131C(2):213-21. PubMed ID: 7416718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C56 formation in the reaction mixture of isolated complement components through the classical complement pathway.
    Kitamura H; Tsuboi M; Nagaki K
    Int Arch Allergy Appl Immunol; 1985; 78(1):101-7. PubMed ID: 4030125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activating property of the protein-rich endotoxin (OEP) of Pseudomonas aeruginosa. I. Activation of both the classical and the alternative pathways of guinea pig complement.
    Inada K
    Jpn J Exp Med; 1980 Feb; 50(1):13-21. PubMed ID: 6770130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease.
    Falk RJ; Dalmasso AP; Kim Y; Tsai CH; Scheinman JI; Gewurz H; Michael AF
    J Clin Invest; 1983 Aug; 72(2):560-73. PubMed ID: 6348093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement-mediated killing of Borrelia burgdorferi by nonimmune sera from sika deer.
    Nelson DR; Rooney S; Miller NJ; Mather TN
    J Parasitol; 2000 Dec; 86(6):1232-8. PubMed ID: 11191897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for restriction of the ability of complement to lyse homologous erythrocytes.
    Houle JJ; Hoffmann EM
    J Immunol; 1984 Sep; 133(3):1444-52. PubMed ID: 6430999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
    Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
    Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.